A Paradigm to Discover Biomarkers Associated With Chronic Kidney Disease Progression

Biomarker discovery in the field of risk prediction in chronic kidney disease (CKD) embraces the prospect of improving our ability to risk stratify future adverse outcomes and thereby guide patient care in a new era of personalised medicine. However, many studies that report biomarkers predictive of...

Full description

Bibliographic Details
Main Authors: Ibrahim Ali, Sara T Ibrahim, Rajkumar Chinnadurai, Darren Green, Maarten Taal, Tony D Whetton, Philip A Kalra
Format: Article
Language:English
Published: SAGE Publishing 2020-11-01
Series:Biomarker Insights
Online Access:https://doi.org/10.1177/1177271920976146
id doaj-03a919bc227f44be9b76278245044f07
record_format Article
spelling doaj-03a919bc227f44be9b76278245044f072020-12-03T04:33:24ZengSAGE PublishingBiomarker Insights1177-27192020-11-011510.1177/1177271920976146A Paradigm to Discover Biomarkers Associated With Chronic Kidney Disease ProgressionIbrahim Ali0Sara T Ibrahim1Rajkumar Chinnadurai2Darren Green3Maarten Taal4Tony D Whetton5Philip A Kalra6Division of Cardiovascular Sciences, University of Manchester, Manchester, UKInternal Medicine and Nephrology Department, University of Alexandria, Alexandria, EgyptDepartment of Renal Medicine, Salford Royal NHS Foundation Trust, Stott Lane, Salford, UKDepartment of Acute Medicine, Salford Royal NHS Foundation Trust, Stott Lane, Salford, UKFaculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UKDivision of Cancer Sciences, University of Manchester, Manchester, UKDivision of Cardiovascular Sciences, University of Manchester, Manchester, UKBiomarker discovery in the field of risk prediction in chronic kidney disease (CKD) embraces the prospect of improving our ability to risk stratify future adverse outcomes and thereby guide patient care in a new era of personalised medicine. However, many studies that report biomarkers predictive of CKD progression share a key methodological limitation: failure to characterise patients’ renal progression precisely. This weakens any observable association between a biomarker and an outcome poorly defined by a patient’s change in renal function over time. In this commentary, we discuss the need for a better approach in this research arena and describe a compelling strategy that has the advantage of offering robust and meaningful biomarker exploration relevant to CKD progression.https://doi.org/10.1177/1177271920976146
collection DOAJ
language English
format Article
sources DOAJ
author Ibrahim Ali
Sara T Ibrahim
Rajkumar Chinnadurai
Darren Green
Maarten Taal
Tony D Whetton
Philip A Kalra
spellingShingle Ibrahim Ali
Sara T Ibrahim
Rajkumar Chinnadurai
Darren Green
Maarten Taal
Tony D Whetton
Philip A Kalra
A Paradigm to Discover Biomarkers Associated With Chronic Kidney Disease Progression
Biomarker Insights
author_facet Ibrahim Ali
Sara T Ibrahim
Rajkumar Chinnadurai
Darren Green
Maarten Taal
Tony D Whetton
Philip A Kalra
author_sort Ibrahim Ali
title A Paradigm to Discover Biomarkers Associated With Chronic Kidney Disease Progression
title_short A Paradigm to Discover Biomarkers Associated With Chronic Kidney Disease Progression
title_full A Paradigm to Discover Biomarkers Associated With Chronic Kidney Disease Progression
title_fullStr A Paradigm to Discover Biomarkers Associated With Chronic Kidney Disease Progression
title_full_unstemmed A Paradigm to Discover Biomarkers Associated With Chronic Kidney Disease Progression
title_sort paradigm to discover biomarkers associated with chronic kidney disease progression
publisher SAGE Publishing
series Biomarker Insights
issn 1177-2719
publishDate 2020-11-01
description Biomarker discovery in the field of risk prediction in chronic kidney disease (CKD) embraces the prospect of improving our ability to risk stratify future adverse outcomes and thereby guide patient care in a new era of personalised medicine. However, many studies that report biomarkers predictive of CKD progression share a key methodological limitation: failure to characterise patients’ renal progression precisely. This weakens any observable association between a biomarker and an outcome poorly defined by a patient’s change in renal function over time. In this commentary, we discuss the need for a better approach in this research arena and describe a compelling strategy that has the advantage of offering robust and meaningful biomarker exploration relevant to CKD progression.
url https://doi.org/10.1177/1177271920976146
work_keys_str_mv AT ibrahimali aparadigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression
AT saratibrahim aparadigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression
AT rajkumarchinnadurai aparadigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression
AT darrengreen aparadigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression
AT maartentaal aparadigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression
AT tonydwhetton aparadigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression
AT philipakalra aparadigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression
AT ibrahimali paradigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression
AT saratibrahim paradigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression
AT rajkumarchinnadurai paradigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression
AT darrengreen paradigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression
AT maartentaal paradigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression
AT tonydwhetton paradigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression
AT philipakalra paradigmtodiscoverbiomarkersassociatedwithchronickidneydiseaseprogression
_version_ 1724401337177735168